Elanco Animal Health
Elanco Animal Health

Elanco Animal Health

Pharmaceuticals
WebsiteInvestor RelationsSEC
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

$13.4B

Market Cap • 11/10/2026

2018

(8 years)

Founded

2018

(8 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2

P/S

2,6

P/EBITDA

15,6

P/OCF

21,8

P/FCF

32,8

P/E

—

BVPS

13,3

EPS

—

Market Cap

Market Cap

13,4B

EV

16,6B

EV/Revenue

3,2

EV/EBITDA

19,4

EV/EBIT

101,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-2,1B

Profitability

Gross Margin

56,2%

EBITDA Margin

16,6%

EBIT Margin

3,2%

Net Margin

—

D&A/EBITDA

65,3%

R&D/Revenue

7,4%

Capex/Revenue

4%

Capex/D&A

29,7%

Capex/OCF

33,6%

SBC/OCF

12,5%

% PPE

10,8%

% Goodwill

36%

ROE

—

ROIC

1,4%

Growth

CAGR Revenue 5Y

1,5%

CAGR Net Income 5Y

-27,1%

CAGR EPS 5Y

-26,7%

CAGR OCF 5Y

29,7%

Leverage

N.D./EBITDA

3,8

Debt/Equity

0%

Current Ratio

2,1

Quick Ratio

0,9

Interest Coverage

63,9%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium